Corrigendum to: Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation (Acta Oncologica, (2015), 54, 4, (487-492), 10.3109/0284186X.2014.990158);Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation

Acta Oncologica

Volumn 54, Issue 4, 2015, Pages 487-492

  Kothari, Nishi ^a   Kim, Richard ^a   Jorissen, Robert N ^b,c   Desai, Jayesh ^b,d   Tie, Jeanne ^b,d,e   Wong, Hui Li ^b,d   Farragher, Ian ^e   Jones, Ian ^d   Day, Fiona L ^b   Li, Shan ^b,c   Sakthinandeswaren, Anuratha ^b,c   Palmieri, Michelle ^b,c   Lipton, Lara ^b,d,e   Schell, Michael ^a   Teer, Jamie K ^a   Shibata, David ^a   Yeatman, Timothy ^f   Sieber, Oliver M ^b,c   Gibbs, Peter ^b,d,e,g   Tran, Ben ^b,d,e  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

^e WESTERN HOSPITAL   (Australia)

^f Gibbs Cancer Center   (United States)

^g BioGrid Australia   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; AUSTRALIA; CANCER CENTER; CANCER PATIENT; CANCER SPECIFIC SURVIVAL; COHORT ANALYSIS; COLORECTAL CANCER; DRUG USE; EXOME; FOLLOW UP; GENE MUTATION; GENE SEQUENCE; HUMAN; MAJOR CLINICAL STUDY; NEXT GENERATION SEQUENCING; OVERALL SURVIVAL; PIK3CA GENE; PRIORITY JOURNAL; TREND STUDY; TUMOR GENE; UNITED STATES; COLORECTAL NEOPLASMS; ERROR; FEMALE; GENETICS; MALE; MIDDLE AGED; MORTALITY; MUTATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES;

EID: 84925446564     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/0284186X.2016.1276746     Document Type: Erratum

References (25)

1. Colorectal cancer incidence, mortality and prevalence worldwide in 2008 Summary, 2010. Available from: http://globo-can.iarc.fr/factsheet.asp. Cited 15th September 2014.
2. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl J Med 2004; 350: 2335-42.
3. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. New Engl J Med 2004; 351: 337-45.
4. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitu-mumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-34.
5. Karaca-Mandic P, McCullough JS, Siddiqui MA, Van Houten H, Shah ND. Impact of new drugs and biolog-ics on colorectal cancer treatment and costs. J Oncol Pract 2011; 7: e30s-7s.
6. Tran B, Keating CL, Ananda SS, Kosmider S, Jones I, Croxford M, et al. Preliminary analysis of the cost-effectiveness of the National Bowel Cancer Screening Program: Demonstrating the potential value of comprehensive real world data. Intern Med J 2012; 42: 794-800.
7. Bardou M, Barkun A, Martel M. Effect of statin therapy on colorectal cancer. Gut 2010; 59: 1572-85.
8. Meyerhardt JA, editor. Beyond standard adjuvant therapy for colon cancer: Role of nonstandard interventions. Semin Oncol 2011: NIH Public Access.
9. Kerr DJ, Dunn JA, Langman MJ, Smith JL, Midgley RS, Stanley A, et al. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. New Engl J Med 2007; 357: 360-9.
10. Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, et al. Aspirin for the chemoprevention of colorectal adenomas: Meta-analysis of the randomized trials. J Natl Cancer Instit 2009; 101: 256-66.
11. Rothwell PM, Wilson M, Elwin C-E, Norrving B, Algra A, Warlow CP, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010; 376: 1741-50.
12. Ogino S, Lochhead P, Giovannucci E, Meyerhardt J, Fuchs C, Chan A. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: Power and promise of molecular pathological epidemiology. Oncogene 2014; 33: 2949-55.
13. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. New Engl J Med 2012; 367: 1596-606.
14. Day FL, Jorissen RN, Lipton L, Mouradov D, Sakthianandeswaren A, Christie M, et al. PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer. Clin Cancer Res 2013; 19: 3285-96.
15. Ikenoue T, Kanai F, Hikiba Y, Obata T, Tanaka Y, Imamura J, et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 2005; 65: 4562-7.
16. Rosty C, Young JP, Walsh MD, Clendenning M, Sanderson K, Walters RJ, et al. PIK3CA activating mutation in colorectal carcinoma: Associations with molecular features and survival. PloS One 2013; 8: e65479.
17. Domingo E, Church DN, Sieber O, Ramamoorthy R, Yanagisawa Y, Johnstone E, et al. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J Clin Oncol 2013; 31: 4297-305.
18. Reimers MS, Bastiaannet E, Langley RE, van Eijk R, van Vlierberghe RL, Lemmens VE, et al. Expression of HLA class I antigen, aspirin use, and survival after a diagnosis of colon cancer. JAMA Intern Med 2014; 174: 732-9.
19. De Berardis G, Lucisano G, D'Ettorre A, Pellegrini F, Lepore V, Tognoni G, et al. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA 2012; 307: 2286-94.
20. Fenstermacher DA, Wenham RM, Rollison DE, Dalton WS. Implementing personalized medicine in a cancer center. Cancer J (Sudbury, Mass) 2011; 17: 528.
21. Tran B, Dancey JE, Kamel-Reid S, McPherson JD, Bedard PL, Brown AM, et al. Cancer genomics: Technology, discovery, and translation. J Clin Oncol 2012; 30: 647-60.
22. Roth GA, Gillespie CW, Mokdad AA, Shen DD, Fleming DW, Stergachis A, et al. Aspirin use and knowledge in the community: A population-and health facility based survey for measuring local health system performance. BMC Cardiovasc Disord 2014; 14: 16.
23. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorec-tal cancer and adenoma in male health professionals. Ann Intern Med 1994; 121: 241-6.
24. Viudez A, Hernandez I, Vera R, de Navarra CH, Liao X, Lochhead P, et al. Aspirin, PIK3CA mutation, and colorec-tal-cancer survival. N Engl J Med 2013; 368: 289.
25. Pasche B. Differential effects of aspirin before and after diagnosis of colorectal cancer. JAMA 2013; 309: 2598-9.